Sanofi-Aventis's Multaq prioritised by US FDA
This article was originally published in Scrip
Sanofi-Aventis's NDA for its amiodarone follow-on drug candidate Multaq (dronedarone) for the prevention of cardiovascular events in patients with atrial fibrillation and atrial flutter has been granted priority review status by theUS FDA.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.